Skip to main content
2024 Guide to Patient Support Services


2024 PSS Guide

Seagen Secure Support Services

Seagen offers the Seagen Secure patient assistance program to help patients while taking a Seagen oncology medication (Table). This program offers a comprehensive suite of programs, including the Commercial Out-of-Pocket Assistance Program, the Patient Assistance Program, and the Quick Start Program, as well as access to Oncology Access Advocates.

Commercial Out-of-Pocket Assistance Program

For patients taking Adcetris or Tivdak, call 855-473-2873 for more information about available out-of-pocket assistance.

Patient Assistance Program

For eligible uninsured and underinsured patients, the Patient Assistance Program provides the product for up to 1 year at no cost to patients who meet program eligibility requirements. Oncology Access Advocates can assess patient eligibility for this program.

Quick Start Program

The Quick Start Program provides a 15-day supply of Tukysa at no cost to patients who experience an insurance-related access delay.

Oncology Access Advocates

Once enrolled in Seagen Secure, patients will be assigned a dedicated Oncology Access Advocate who can assist with any coverage or financial issues.

To learn more or to enroll your patient in Seagen Secure, call 855-473-2873 or visit

TABLE Seagen Oncology Drugs

Patient support programs

Tivdak (tisotumab vedotin-tftv) for injection
Treatment of adult patients with recurrent or metastatic cervical cancer with disease progression on or after chemotherapy
Patient support programs

Adcetris (brentuximab vedotin) Indications

Treatment of adult patients with untreated stage III or IV classical Hodgkin lymphoma, in combination with doxorubicin, vinblastine, and dacarbazine; pediatric patients age ≥2 years with untreated high-risk classical Hodgkin lymphoma, in combination with doxorubicin, vincristine, etoposide, prednisone, and cyclophosphamide; adults with classical Hodgkin lymphoma at high risk for relapse or progression after autologous hematopoietic stem cell transplant (HSCT) consolidation; adults with classical Hodgkin lymphoma, after failure of autologous HSCT, or after ≥2 multiagent chemotherapy regimens if ineligible for transplant; adults with untreated systemic anaplastic large cell lymphoma or other CD30-expressing peripheral T-cell lymphoma, in combination with cyclophosphamide, doxorubicin, and prednisone; adults with systemic anaplastic large cell lymphoma after failure of ≥1 multiagent chemotherapy regimens; adults with primary cutaneous anaplastic large cell lymphoma, or CD30-expressing mycosis fungoides after systemic therapy

Tukysa (tucatinib) tablets

Treatment, in combination with trastuzumab and capecitabine, of adults with advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received ≥1 HER2-targeted regimens in the metastatic setting; treatment, in combination with trastuzumab, of adults with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer that has progressed after treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy